Publications
2025
LONG-TERM INFECTION RISK IN MODERATE-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS FROM THE BRITISH ISLES LUPUS ASSESSMENT GROUP BIOLOGICS REGISTER (BILAG-BR): A PROSPECTIVE LONGITUDINAL STUDY
Achieng, S., Dyball, S., Rodziewicz, M., Sutton, E., Parker, B., Wootton, D., . . . Bruce, I. (2025). LONG-TERM INFECTION RISK IN MODERATE-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS FROM THE BRITISH ISLES LUPUS ASSESSMENT GROUP BIOLOGICS REGISTER (BILAG-BR): A PROSPECTIVE LONGITUDINAL STUDY. The Journal of Rheumatology, 52(Suppl 1), 65-66. doi:10.3899/jrheum.2025-0390.pt003
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. (2025). Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.. The Lancet. Infectious diseases, S1473-3099(25)00093-3. doi:10.1016/s1473-3099(25)00093-3
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. (2025). Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.. EClinicalMedicine, 81, 103080. doi:10.1016/j.eclinm.2025.103080